Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study by Hasniza Zaman Huri & Hoo Fun Wee
Zaman Huri and Fun Wee BMC Endocrine Disorders 2013, 13:2
http://www.biomedcentral.com/1472-6823/13/2RESEARCH ARTICLE Open AccessDrug related problems in type 2 diabetes patients
with hypertension: a cross-sectional retrospective
study
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Background: Type 2 diabetes (T2DM) patients with hypertension are at increased risk for experiencing drug-related
problems (DRPs) since they often receive multiple medications and have multiple comorbidities. To date, there is a
lack of studies conducted in T2DM patients with hypertension. This study aims to analyze the DRPs and identify
factors affecting the DRPs in this patient population.
Method: This retrospective study involved T2DM patients with hypertension and was conducted at a tertiary
hospital in Malaysia from January 2009 to December 2011. The assessment of DRPs was based on the
Pharmaceutical Network Care Europe (PCNE) tool version 5.01.
Results: Two hundred patients with a total of 387 DRPs were identified. Among these patients, 90.5% had at least
one DRP, averaging 1.9 ± 1.2 problems per patient. The most common DRPs encountered were insufficient
awareness of health and diseases (26%), drug choice problems (23%), dosing problems (16%) and drug interactions
(16%). The most implicated drugs were aspirin, clopidogrel, simvastatin, amlodipine and metformin. The six
domains of DRPs found to have statistically significant associations were renal impairment, polypharmacy,
cardiovascular disease, elderly status, and duration of hospital stay.
Conclusions: Early identification of the types and patterns of DRPs and the factors associated to them may
enhance the prevention and management of DRPs in T2DM patients with hypertension.
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Malaysia is one of the top ten countries in the world
with the greatest number of diabetes patients [1] and the
prevalence has increased dramatically from 8.3% in 1996
to 14.9% in 2006, affecting 1.4 million adults aged ≥
30 years old [2]. According to the results of DiabCare
Malaysia 2008, Type 2 diabetes (T2DM) accounts for
more than 90% of all cases in adults [3]. Hypertension is
a common comorbidity in T2DM patients, with a preva-
lence of up to two-thirds of the population, and it may
be present by the time T2DM is diagnosed or even be-
fore the onset of hyperglycemia [4]. Hypertension
enhances the risk of cardiovascular disease in T2DM
patients [4]. It also increases the risk of developing* Correspondence: hasnizazh@um.edu.my
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distribution, and reproduction in any mediummicrovascular complications such as diabetic nephropa-
thy and retinopathy [5,6].
To minimize the risk of complications, many guide-
lines recommend a target blood pressure (BP) of ≤ 130/
80 mmHg in all T2DM patients with hypertension
[4,7,8]. However, achieving this target BP remains a great
challenge and the majority of the patients require one or
more antihypertensive agents in order to achieve this
optimal BP control [9].
T2DM patients with hypertension often receive mul-
tiple medications and this can lead to the occurrence of
drug-related problems (DRPs) [9]. A high prevalence of
DRPs has been observed in T2DM patients [10,11].
DRPs may lead to suboptimal blood pressure control
[12] which can contribute to significant morbidity or
mortality, prolonged hospitalization, and increasedMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in most cases, these DRPs are preventable [14].
There are several factors influencing DRPs in T2DM
patients with hypertension. Polypharmacy (≥ 5 concurrent
medications) is an inherent factor as high blood pressure
and diabetic complications usually complicate the treat-
ment [9]. Age status (≥ 65 years old) is another factor,
given increased association with multiple medical condi-
tions, multiple drug therapies and age-related changes in
the pharmacokinetics and pharmacodynamics of drugs
[9]. Multiple medical conditions and renal impairment
also have been shown to contribute to DRPs [15,16].
To date, there has been a lack of studies conducted lo-
cally and globally to investigate and document DRPs in
T2DM patients with hypertension. Our study’s aim was
to provide baseline data regarding DRPs to allow the im-
plementation of more effective management and to re-
duce the mortality and morbidity associated with DRPs.
Objectives
1. To assess the drug-related problems in type 2
diabetes patients with hypertension.
2. To identify the factors influencing drug-related
problems in type 2 diabetes patients with hypertension.
Methods
Study design and setting
This was a retrospective study conducted in Malaysia’s
premier teaching hospital with 1000-beds, the University
of Malaya Medical Centre (UMMC).
Study population
A total of 200 patients were included in this study. The
sample size was calculated using the Epi Info, Version 6
(Centers for Disease Control and Prevention, Atlanta
GA), which provided a minimum sample size of 195
patients. The study population consisted of T2DM
patients with hypertension who fulfilled the require-
ments of the International Classification of Diseases
Tenth Revision (ICD-10) code E11.0-11.9 for T2DM and
who were admitted to the UMMC from January 2009 to
December 2011. The study complied with the Declar-
ation of Helsinki and the ethics committee of UMMC
granted its approval. An overview of the study procedure
is shown in Figure 1.
Inclusion criteria
1. Patients diagnosed with T2DM and hypertension
2. Patients who received at least one antidiabetic drug
(oral antidiabetic drug or insulin) and at least one
antihypertensive agent in the ward
3. Adult patients aged 18 years old and aboveExclusion criteria
1. Patient with missing dataData collection
Data were collected by the authors who are pharmacists.
Demographic characteristics such as age, gender, ethni-
city, height, weight, and body mass index were recorded.
Clinical characteristics such as duration of hospital stay,
duration of T2DM, duration of hypertension, presence
of diabetic complications (referred to diabetic retinop-
athy, neuropathy or diabetic foot ulcer), presence of
comorbidities, laboratory results and concurrent medica-
tions were also collected.Definition used in the study
 Comorbidities were defined as chronic illnesses or
diseases which require long term treatment [17].
 Cardiovascular events referred to the presence of
acute coronary syndromes, ischemic heart disease,
heart failure, arrhythmias, cardiomyopathy or as
stated in the medical records [18].
 Renal impairment was defined as chronic kidney
disease, chronic interstitial nephritis, chronic
glomerulonephritis, creatinine clearance of less than
35 mL/min, diabetic nephropathy, nephrosclerosis
or as stated in the medical records [19]. The
assessment of the creatinine clearance with the use
of drugs was based on BNF and Lexicomp.
 Liver impairment referred to liver cirrhosis, chronic
hepatitis, hepatocellular carcinoma, elevations of
liver enzymes (more than 3 times the upper normal
limits) or as stated in the medical records [19,20].
 Polypharmacy was defined as the use of five or more
medications [21].
 DRP is defined as “an event or circumstance
involving drug therapy that actually or potentially
interferes with desired health outcomes” [22].
 Significant potential drug interactions are defined as
interactions that potentially can cause harm to
patient and are well documented or can cause
moderate harm without well documented studies
[23].
Note: The same drug used with different strengths was
counted as one item whereas the same drug with differ-
ent routes of administration was counted as separate
items. Combinations of drugs were counted as a single
item. However, this did not apply to antidiabetic and
antihypertensive drugs, where the number of drugs used
was counted according to the number of classes.
A list of patients who fulfilled the requirements of the ICD-10 code E11.0-11.9 for 
T2DM and admitted to the UMMC from January 2009 to December 2011 was  
generated from Medication Management and Use System (MMUS)  
(535 patients)
Patients' medical records and medication 
records were succesfully retrieved
(422 patients)
All the patients were screened for hypertension 





Approval by the Medical Ethics Committee of the UMMC
Failed to obtain 
medical records or 
missing data
(113 patients)
Figure 1 Overview of study procedure.
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The Pharmaceutical Care Network Europe (PCNE) clas-
sification of DRPs version 5.01 [22] was used to
categorize DRPs. It is an established system that has
been revised several times and its validity and reproduci-
bility have been tested [11,24]. It has been used by many
recent studies [11,21,25].
In this study, the six domains of problems of the
PCNE classification were used. The DRPs and their pos-
sible causes were identified from the patients’ medical
records, with reference to the standard guidelines and
established literatures [4,7,8,26,27]. Two main references
were used to assess the appropriateness of drug indica-
tions, appropriateness of drug and dosage, possible druginteractions, adverse drug reactions and contraindica-
tions [28,29]. The authors who are pharmacists were
involved in the identification and classification of DRPs.
Modified Beers criteria
The modified Beers criteria [30,31] were used in this
study. This is a consensus-based drug list that includes a
number of drugs which should be avoided or used very
cautiously in the elderly. For this study, the criteria were
used as a reference to assess and identify the potential
drugs that were inappropriately prescribed in the T2DM
patients with hypertension who were aged 65 and above.
The listed drugs were generally divided into low and
high risk. In this study, only inappropriate prescriptions
Table 1 Demographic and clinical characteristic of the
patients (N = 200)







Duration of hospital stay
Not more than 7 days 143 (71.5)
8 to 14 days 38 (19.0)
More than 15 days 19 (9.5)
Duration of type 2 diabetes mellitus
Not more than 10 years 72 (36.0)
11 to 20 years 47 (23.5)
21 to 30 years 31 (15.5)
Unknown duration 50 (25.0)
Duration of hypertension
Not more than 10 years 82 (41.0)
11 to 20 years 43 (21.5)
21 to 30 years 22 (11.0)
Unknown duration 53 (26.5)
A1c
Achieved target (< 6.5) 48 (24.0)
Did not achieve target (≥ 6.5) 146 (73.0)
Unknown 6 (3.0)
Diabetic complications*
Diabetic retinopathy 43 (21.5)
Diabetic foot ulcer 21 (10.5)
Diabetic neuropathy 17 (8.5)
Comorbidities†
Renal impairment 100 (50.0)
Cardiovascular disease 96 (48.0)
Dyslipidemia 64 (32.0)
Stroke 40 (20.0)
Gastrointestinal disease 14 (7.0)
Liver impairment 11 (5.5)
Bronchial asthma 7 (3.5)
Benign prostatic hyperplasia 7 (3.5)
Gouty arthritis 6 (3.0)
Osteoarthritis 5 (2.5)
†One patient may have more than one diabetic complication or comorbidity.
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DRPs because these drugs might pose clinically signifi-
cant adverse effects when used in the elderly.
Statistical Techniques
The statistical software Statistical package for Social Sci-
ence (SPSS) version 19 (SPSS Inc., Chicago, IL, USA)
was used to analyze all the data collected and extracted
in this study. Categorical data were expressed as percen-
tages and continuous data were expressed as mean ±
standard deviation. Independent Student’s t-tests were
used to compare group means of continuous dependent
variables while the Kolmogorov-Smirnov Test of Nor-
mality were used to test the distribution of a sample.
In addition, the association or correlation between two
categorical variables was examined using the chi-square
test of independence. Statistical significance was defined
as p-value < 0.05. Refer to Figure 1.
Results
A total of 200 patients were included in this study. The
mean age of patient was 62.3 ± 12.7 years old and the
non-elderly patients were 15.0% more numerous than the
elderly patients. The minimum and maximum ages of the
patients were 31 and 95 years old, respectively. Table 1
demonstrates the demographic and clinical characteristics
of this study population. There was an average of 4.6 ± 1.3
chronic illnesses per patient. The mean number of medi-
cations was 6.9 ± 2.8. The number of medications taken
by patients ranged from 3 to 20. Polypharmacy was com-
mon as 76.5% of the patients were taking five or more
medications, of whom 46.4% were elderly patients.
Patients on combination therapy were 4.5% more nu-
merous than patients on monotherapy, and the most fre-
quently used drug classes were calcium channel
blockers, ACE inhibitors and diuretics. Amlodipine, peri-
ndopril and frusemide were the most widely used agents
representing these classes, respectively.
The dual therapy that had the highest frequency was
ACE inhibitors plus calcium channel blockers (5%), fol-
lowed by ACE inhibitors plus beta blockers (4.5%). The
combination of ACE inhibitors, calcium channel block-
ers and beta blockers (4%) was the most commonly used
triple therapy. Additionally, 2 out of the 19 patients
received antihypertensive agents from 5 different classes.
More than two-thirds of the patients were on mono-
therapy with oral antidiabetic agents or insulin. Insulin
was more widely used than oral agents, with a difference
of 17.5%. For combination therapy, oral agents plus in-
sulin (17.5%) appeared to be the most common combin-
ation. Of these, insulin plus a single antidiabetic agent
had the highest frequency (14%).
Insulin was the most common antidiabetic prescribed.
The most frequently used oral agents were biguanides(metformin) and sulfonylureas. The use of acarbose
(alpha-glucosidase inhibitors) and sitagliptin (dipeptidyl
peptidase-4 inhibitors) were 3.2% and 0.6%, respectively.
A total number of 387 DRPs were identified (Table 2).
There was an average of 1.9 ± 1.2 problems and 1.7 ± 1.1
causes per patient. A total of 90.5% of the patients had
Table 2 Drug related problems in type 2 diabetes patients with hypertension (n = 387)
Code Problems* Number of problem (Percentage, %)
P1 Adverse reactions 25 (6.5)
P1.1 Side effects suffered (non-allergic) 25 (6.5)
P2 Drug choice problems 87 (22.5)
P2.1 Inappropriate drug (not most appropriate for indication) 34 (8.8)
P2.2 Inappropriate drug form (not most appropriate for indication) 4 (1.0)
P2.3 Inappropriate duplication of therapeutic group or active ingredient 4 (1.0)
P2.4 Contraindication for drug 29 (7.5)
P2.5 No clear indication for drug use 1 (0.3)
P2.6 No drug but clear indication 15 (3.9)
P3 Dosing problems 62 (16.0)
P3.1 Drug dose too low or dosage regime not frequent enough 5 (1.3)
P3.2 Drug dose too high or dosage regime too frequent 44 (11.3)
P3.3 Duration of treatment too short 8 (2.1)
P3.4 Duration of treatment too long 5 (1.3)
P4 Drug use problems 50 (12.9)
P4.1 Drug not taken/administered at all 50 (12.9)
P5 Interactions 63 (16.3)
P5.1 Potential interaction 63 (16.3)
P6 Others 100 (25.8)
P6.1 Patient dissatisfied with therapy despite taking drug(s) correctly 5 (1.3)
P6.2 Insufficient awareness of health and diseases (possibly leading to future problems) 90 (23.2)
P6.4 Therapy failure (reason unknown) 5 (1.3)
*Only problems that have a frequency of more than one were included.
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were “others”, drug choice problems and drug interac-
tions. The mean number of chronic illnesses was 2.65 ±
1.3 in the group of patients with DRPs and 2.1 ± 1.1 in
the group of patient without DRPs. There was a signifi-
cant difference (p = 0.039) between the two group when
tested using the independent sample t-test. Under the
“others” category, the most frequent problem encoun-
tered was the “insufficient awareness of health and dis-
eases,” accounting for 22% of all the cases. On the other
hand, most of the drug choice problems were the results
of inappropriate drug selection and the use of contrain-
dicated drugs.
A total of 25 adverse reactions were reported (Table 2).
Antidiabetic drugs were associated with about one-third
of all the cases. Eight patients experienced hypoglycemia
secondary to either oral antidiabetic drugs or insulin.
Tremor secondary to insulin was also recorded. Antihy-
pertensive agents that caused adverse reactions were cal-
cium channel blockers, diuretics and ACE inhibitors. It
was reported that amlopidine had caused increased heart
rate and bilateral leg swelling. Electrolyte imbalances
were reported as adverse reactions of perindopril (hyper-
kalemia) and indapamide (hyponatremia). Also, urinary
hesitancy secondary to hydrochlorothiazide had been
reported. One patient suffered from rhabdomyolysissecondary to a lipid lowering agent. Drugs that did not
fall into the above three classes were classified as
“others”. For example, bleeding gums and hematuria sec-
ondary to warfarin had been reported. Also, steroids had
been associated with two cases of adverse reactions.
Among the 87 drug choice problems identified, most of
the problems were related to inappropriate drug choice
and contraindications. The distribution of the drug
choice problem is displayed in Table 2. Antihypertensive
drugs were not used appropriately. The inappropriate
choice of antihypertensive drugs resulted in 19 drug
choice problems. For example, ACE inhibitors were used
in five patients with ESRD. Alpha blockers such as pra-
zosin and doxazosin were used as second or third add-
on therapies when other better alternatives were avail-
able and not contraindicated (7 patients). Short-acting
nifedipine was used in two elderly patients and spirono-
lactone was prescribed to two renal impairment patients
with creatinine clearances of less than 30 mL/minute.
Aspirin was also given to patients with severe renal im-
pairment who had creatinine clearances of less than
10 mL/minute.
In addition to these, there were several drugs which
were inappropriately used in the elderly and were classi-
fied as high risk under the modified Beers criteria,
namely, ticlopidine (4 cases), amitriptyline (2 cases),
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chlorpheniramine, and others.
Twenty-eight drug choice problems involving the use
of contraindicated drugs were identified. The three most
common drugs that were most prescribed in the pres-
ence of contraindications were metformin, aspirin and
fondaparinux. For instance, metformin was prescribed in
18 patients for whom it was contraindicated (e.g., cre-
atinine clearance less than 30 mL/minute, more than
80 years old, or recent myocardial infarction). Also, gli-
clazide was prescribed to five patients with severe liver
impairment and aspirin was given to patients who had a
previous history of allergy. Three patients received fon-
daparinux despite their poor renal function (creatinine
clearances of less than 30 mL/minute).
There were 15 cases where no drugs were prescribed
for a clear indication. For example, hematinics were
indicated in ESRD patients with chronic anemia but no
drugs were prescribed (10 cases). Also, aspirin or sim-
vastatin were not given to some of the patients as sec-
ondary prophylaxis of CVD.
Of the 62 cases of inappropriate dosing identified, most
of the drugs were prescribed at a higher dose than
required, particularly in patients with existing renal or liver
impairments. The most common drugs that were involved
in wrong dosages were H2-antogonists (20 cases), antibio-
tics (8 cases), antihypertensive agents (6 cases), antidiabetic
drugs (3 cases) and others. Ranitidine was commonly pre-
scribed at a higher dosage than required in patients with
creatinine clearances of less than 50 mL/minute.
In addition to wrong dosages, inappropriate durations
of treatment were also identified. Durations of treatment
were too short in eight cases whereas longer than required
in four cases. For example, oseltamivir (TamifluW) was
only given for three days for the treatment of H1N1 and
oral azithromycin 500 mg was administered once daily for
six days.
One-quarter of the patients had at least one drug use
problem and this made up approximately 13% of all the
DRPs. It was recorded in the patients’ medical records
that drugs were not taken or administered by them prior
to admission. Non-compliance with antihypertensive
agents and antidiabetic drugs was frequent.
There were a total of 63 significant potential drug
interactions identified. The use of aspirin and clopido-
grel posed a significant potential drug interaction in 25
patients. In addition, there were 14 patients who were
prescribed simvastatin at more than 20 mg while receiv-
ing amlodipine. In this study, the drugs most implicated
in drug interactions were aspirin (32 cases), clopidogrel
(31 cases), simvastatin (23 cases), amlodipine (15 cases),
omeprazole (15 cases), and iron salts (9 cases).
About one-quarter of the DRPs that could not be classi-
fied under any other category were regarded as “Others”.The majority of patients had insufficient awareness of
health and diseases which could possibly lead to future
problems. For example, many patients had a lack of know-
ledge about T2DM. Also, they were unaware of the man-
agement of the disease and its complications.
The total number of causes identified was 336
(Table 3). The causes varied with the problems identi-
fied. Some problems might have more than one cause
whereas some might not have any causes. For example,
most of the drug interactions did not have a cause. Of
all the causes identified, inappropriate drug selection
was the cause with the highest frequency, followed by
inappropriate dosage selection and burden of therapy.
When matching the cause to the problem, inappropri-
ate drug or dose selection was found to be the most
common cause for drug choice problems and dosing
problems. The main cause for adverse reaction was “pa-
tient or psychological”, particularly “patient has concerns
with drugs”. Drug use problems were commonly caused
by “patient or psychological”, followed by “drug use
process”. Similarly, “patient or psychological” was the
most common cause for “other” problems.
There was no statistical significance identified when
comparing factors with DRPs (Tables 4, 5). Despite this,
several factors were found to have a statistically signifi-
cant association with the 6 domains of DRPs. The eld-
erly had a positive statistical association with drug
choice problems (p < 0.001). Also, there were significant
associations between renal impairment and drug choice
problems (p = 0.029) or dosing problems (p = 0.027).
In addition, polypharmacy (p = 0.001) and cardiovas-
cular events (p < 0.001) were found to be associated
with drug interactions. Patients with polypharmacy or
cardiovascular disease were more susceptible to poten-
tial drug interactions than those without these two fac-
tors. Moreover, a positive association between length of
hospital stay and drug choice problem was discovered
(p = 0.004). Those who stayed not more than one week
had a higher likelihood of experiencing a drug choice
problem.
Discussion
The mean age of this study population was higher com-
pared with published local data which evaluated the dia-
betes control of 1670 patients in Malaysia [3]. Both local
and global data revealed that in developing countries like
Malaysia, the prevalence of diabetes mellitus was highest
in the age group between 45 and 64 years [2] but in this
study only 36% of the patients fell into this age group.
The higher mean age reported in this study might be be-
cause the sample was not representative of the whole
population. It also suggests that more older hypertensive
diabetic patients were admitted to the ward than were
younger patients.
Table 3 Causes of DRPs in T2DM patients with hypertension (n = 336)
Code Causes* Number of problem (Percentage, %)
C1 Drug/Dose selection 158 (47.0)
C1.1 Inappropriate drug selection 70 (20.8)
C1.2 Inappropriate dosage selection 58 (17.2)
C1.5 Synergistic/preventive drug required and not given 15 (4.5)
C1.8 Manifest side effect, no other cause 15 (4.5)
C2 Drug use process 36 (10.7)
C2.1 Inappropriate timing of administration and/or dosing intervals 2 (0.6)
C2.2 Drug underused/under-administered 33 (9.8)
C2.6 Patient unable to use drug/form as directed 1 (0.3)
C3 Information 13 (3.9)
C3.1 Instructions for use/taking not known 1 (0.3)
C3.2 Patient unaware of reason for drug treatment 6 (1.8)
C3.4 Patient unable to understand local language 6 (1.8)
C4 Patient/Psychological 124 (36.9)
C4.1 Patient forgets to use/take drug 14 (4.2)
C4.2 Patient has concerns with drugs 4 (1.2)
C4.3 Patient suspects side-effect 10 (3.0)
C4.5 Patient unwilling to bother physician 6 (1.8)
C4.7 Patient unwilling to adapt life-style 28 (8.3)
C4.8 Burden of therapy 47 (14.0)
C4.9 Treatment not in line with health beliefs 15 (4.4)
C5 Logistic 5 (1.5)
C5.1 Prescribed drug not available (anymore) 3 (0.9)
C5.2 Prescribing error (only in case of slip of the pen) 2.(0.6)
*Only causes that have frequency of more than one were included.
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In this study, there was an average of 1.9 ± 1.2 DRPs per pa-
tient. To date, there has been no comparable study done
specifically on DRPs in T2DM patients with hypertension
both locally and globally. The number of DRPs identified
was only half the number detected by some other studies
which were conducted in diabetes mellitus patients
[10,11,25]. When compared with a recent study with an al-
most equivalent sample size (193 geriatric clinic patients in
Taiwan), which also used the PCNE classification system,
the average number of problems identified was 2.2 ± 1.6 per
patient, slightly higher than in this study [21].
Although a similar PCNE classification of DRPs was
used, the discrepancy with the study by Van Roozendaal
et al. (2009) [11] could be due to the different methods
and references used to identify DRPs. For example, the
concurrent use of an ACE inhibitor and a sulfonylurea
or insulin was considered as a potential DRP in that
study and accounted for 46 cases out of the 682 DRPs
detected. However, this combination of drugs was not
considered as a potential drug interaction in this study
because there is a lack of strong evidence of interaction
[29]. Also, Van Roozendaal et al. (2009) [11] could not
identify any possible contraindications as no informationon patients’ renal and hepatic functions were success-
fully retrieved but this is not the case in this study as
several contraindications were identified based on
patients’ medical records and laboratory results.
Apart from that, the discrepancy with other studies
may be attributed to the differences in study method
and setting, different classification systems of DRPs used,
and different methods to assess DRPs. Both the studies
by Haugbolle & Sorensen (2006) [10] and Eichenberger
et al. (2011) [25] conducted home visits and interviews.
Also, the Problem Intervention Documentation (PI-Doc)
coding system was used in the study by Haugbolle &
Sorensen (2006)[10] whereas the classification system of
DRPs used by Eichenberger et al. (2011)[25] was unclear,
as it was not mentioned in its Methods section. Also,
the clinical knowledge of the investigator(s) might also
influence the assessment and identification of DRPs.
This study revealed that 90.5% of the patients had at
least one DRP, which was much greater than the 80.7%
reported by Haugbolle & Sorensen (2006) [10]. However,
in a study conducted on ambulatory hemodialysis patients,
97.7% of the patients were found to have at least one DRP
[32]. This variation across the studies can be attributed to
the different study populations and study methods.
Table 4 Comparison between factors and occurrence of adverse reactions, drug choice problems, and dosing problems
Factors Adverse reactions (n = 25) Frequency
(Percentage, %)
Drug choice problem (n = 76) Frequency
(Percentage, %)
Dosing problem (n = 55) Frequency
(Percentage, %)
Yes No p-value Yes No p-value Yes No p-value
Elderly
Yes 11 (44.0) 74 (42.3) > 0.999a 28 (36.8) 87 (70.2) < 0.001a* 34 (61.8) 81 (70.4) 0.548a
No 14 (56.0) 101(57.7) 48 (63.2) 37 (29.8) 21 (38.2) 64 (29.6)
Polypharmacy
Yes 19 (76.0) 134 (76.6) > 0.999a 60 (78.9) 93 (75.0) 0.640a 38 (69.1) 115 (79.3) 0.182a
No 6 (26.0) 41 (23.4) 16 (21.1) 31 (25.0) 17 (30.9) 30 (20.7)
Duration of hospital stay
≤ 1 week 17 (68.0) 126 (72.0) 0.859a 45 (59.2) 98 (79.0) 0.004a* 40 (72.7) 103 (71.0) 0.951a
> 1 week 8 (32.0) 49 (28.0) 31 (40.8) 26 (21.0) 15 (27.3) 42 (29.0)
Microvascular complications
Yes 17 (68.0) 107 (61.1) 0.660a 53 (69.7) 71 (57.3) 0.106a 40 (72.7) 84 (57.9) 0.078a
No 8 (32.0) 68 (38.9) 23 (30.3) 53 (42.7) 15 (27.3) 61 (42.1)
Cardiovascular events
Yes 12 (48.0) 109 (62.3) 0.193b 47 (61.8) 74 (59.7) 0.877a 36 (65.5) 85 (58.6) 0.471a
No 13 (52.0) 66 (37.7) 29 (38.2) 50 (40.3) 19 (34.5) 60 (41.4)
Renal impairment
Yes 12 (48.0) 88 (50.3) > 0.999a 46 (60.5) 54 (43.5) 0.029a* 35 (63.6) 65 (44.8) 0.027a*
No 13 (52.0) 87 (49.7) 30 (39.5) 70 (56.5) 20 (36.4) 80 (55.2)
Liver impairment
Yes 1 (4.0) 10 (5.7) > 0.999b 6 (7.9) 5 (4.0) 0.399a 5 (9.1) 6 (4.1) 0.306a
No 24 (96.0) 165 (94.3) 70 (92.1) 119 (96.0) 50 (90.9) 139 (95.9)
Hyperlipidemia
Yes 7 (28.0) 57 (32.6) 0.819a 17 (22.4) 47 (37.9) 0.033a* 15 (27.3) 49 (33.8) 0.476a
No 18 (72.0) 118 (67.4) 59 (77.6) 77 (62.1) 40 (72.7) 96 (66.2)
a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).
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In this study, almost one-third of the adverse drug reac-
tions implicated antidiabetic drugs. Similar to the finding
by Van Roozendaal & Krass (2008) [11], there was a po-
tential risk of hypoglycemia in patients receiving oral
antidiabetic drugs or insulin. Antihypertensive agents
were also commonly associated with adverse reactions
[33] and this finding was clearly demonstrated in this
study. Calcium channel blockers caused a higher inci-
dence of adverse reactions than diuretics, consistent with
a study in an outpatient setting by Goncalves et al.
(2007) [34]. Therefore, all these potential adverse reac-
tions should be taken into consideration, especially in
the elderly who might suffer significant deleterious
effects. However, since this study was retrospective in
nature, only the ones that were important for the hos-
pital admission were noted.
Drug choice problems
A drug choice problem was the second most common
DRP in this study and this finding was comparable to
other studies [10,11]. In this study, most of thecontraindications identified were related to the use of met-
formin. Approximately 24% of the patients who received
metformin were found to have contraindications. This was
much less compared with the study carried out by Sweileh
(2007) [35], in which up to 60% of the patients receiving
metformin had contraindications to it. This difference is
probably due to the variations in defining metformin’s
contraindications. For instance, the decompensated stage,
but no other stage of congestive heart failure, was defined
as a contraindication in this study.
Apart from metformin, drugs that were categorized as
high risk in the modified Beers criteria were frequently
prescribed to the elderly, placing them at higher risk of
developing drug toxicity [4,31]. The high frequency of
drug choice problems may highlight a need for the health
care providers to pay more attention when prescribing
these drugs to older hypertensive diabetic patients.
Dosing problems
In this study, excessive dosage was the most frequent
dosing problem. Also, there were cases of subtherapeutic
dosages and inappropriate durations of treatment. The
Table 5 Comparison between factors and occurrence of drug use problems, drug interactions, and other problems
Factors Drug use problems (n = 50) Frequency
(Percentage, %)
Drug interactions (n = 63) Frequency
(Percentage, %)
Other problems (n = 97) Frequency
(Percentage, %)
Yes No p-value Yes No p-value Yes No p-value
Elderly
Yes 17 (34.0) 68 (45.3) 0.215a 37 (58.7) 78 (56.9) 0.933a 57 (58.8) 58 (56.3) 0.836a
No 33 (66.0) 82 (54.7) 26 (41.3) 59 (43.1) 40 (41.2) 45 (43.7)
Polypharmacy
Yes 34 (68.0) 119 (79.3) 0.149a 58 (92.1) 95 (69.3) 0.001a* 74 (76.3) 79 (76.7) > 0.999a
No 16 (32.0) 31 (20.7) 5 (7.9) 42 (30.7) 23 (23.7) 24 (23.3)
Duration of hospital stay
≤ 1 week 37 (74.0) 106 (70.7) 0.786a 44 (69.8) 99 (72.3) 0.854a 65 (67.0) 78 (75.7) 0.227a
> 1 week 13 (26.0) 44 (29.3) 19 (30.2) 38 (27.7) 32 (33.0) 25 (24.3)
Microvascular complications
Yes 31 (62.0) 93 (62.0) > 0.999a 41 (65.1) 83 (60.6) 0.652a 65 (67.0) 59 (57.3) 0.204a
No 19 (38.0) 57 (38.0) 22 (34.9) 54 (39.4) 32 (33.0) 44 (42.7)
Cardiovascular disease
Yes 27 (54.0) 94 (62.7) 0.358a 53 (84.1) 68 (49.6) < 0.001a* 63 (64.9) 58 (56.3) 0.270a
No 23 (46.0) 56 (37.3) 10 (15.9) 69 (50.4) 34 (35.1) 45 (43.7)
Renal impairment
Yes 22 (44.0) 78 (52.0) 0.414a 33 (52.4) 67 (48.9) 0.761a 49 (50.5) 51 (49.5) > 0.999a
No 28 (56.0) 72 (48.0) 30 (47.6) 70 (51.1) 48 (49.5) 52 (50.5)
Liver impairement
Yes 4 (8.0) 7 (4.7) 0.472b 0 (0) 11 (8.0) 0.018b* 5 (5.2) 5 (5.8) > 0.999a
No 46 (92.0) 143 (95.3) 63 (100) 126 (92.0) 92 (94.8) 97 (94.2)
Hyperlipidemia
Yes 17 (34.0) 68 (45.3) 37 (58.7) 78 (56.9) 57 (58.8) 58 (56.3) 0.836a
No 33 (66.0) 82 (54.7) 0.215a 26 (41.3) 59 (43.1) 0.933a 40 (41.2) 45 (43.7)
a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).
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than that reported by Van Roozendaal and Krass (2009)
[11] and this was probably due to the lack of assessment
of patients’ renal and hepatic functions in the latter
study.
Ranitidine was the most implicated drug for dosing
problems. In clinical practice, dosage adjustments of ra-
nitidine are not frequently applied although recom-
mended by manufacturers and this is probably because
its potential adverse effects are underestimated [36,37].
In a study by Manlucu et al. (2005) [37], H2-receptor
antagonists were demonstrated to significantly increase
the area under the curve (AUC) and the elimination
half-life (t1/2) of serum drug concentrations when the
glomerular filtration rate (GFR) was decreasing. Dosage
reduction of drugs in patients with impaired renal func-
tion and low GFR may prevent adverse effects and de-
crease unnecessary drug expenditures [36,37]. Therefore,
efforts should be made to minimize these dosing errors
such as the involvement of a pharmacist in deciding the
dosing of drugs or a computerized dosing program [37].Drug use problem
The most frequent drug use problem encountered was
“drugs not taken by patients prior to admission”, which
were mostly antihypertensive and antidiabetic drugs. In
this study, forgetfulness might be one of the reasons for
non-adherence. Also, complicated regimens for the
treatment of diabetic complications may contribute to
non-adherence. A systematic review confirmed the poor
compliance in diabetic patients who were prescribed dia-
betic medications, whether oral agents or insulin [12].
Non-adherence has proven to be associated with nega-
tive outcomes such as higher A1c levels and blood lipid
levels in diabetes patients [12,38].
Drug interactions
In this study, the drugs that were most implicated in drug
interactions were aspirin, clopidogrel, simvastatin and
amlodipine. By contrast, beta-blockers, non-steroidal anti-
inflammatory agents (NSAIDs) and ACE inhibitors were
the drug most involved in drug interactions in a study con-
ducted in Singapore [39]. The differences in prescribing
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this discrepancy. The drug interactions identified in this
study were mostly based on established literature and evi-
dence. In clinical practice, several drugs can still be used
together, yet close monitoring is fundamental and any tox-
icity should be identified and immediately followed by cor-
rective actions.
Others
Many of the patients in this study did not engage in
regular physical activity, did not adhere to diabetic diets,
did not perform any routine blood glucose monitoring,
and defaulted on follow-up or medications, and all these
problems were clearly stated by the health care providers
in the medical records. These problems would lead to
poor glycemic control and accelerate the development
or worsening of diabetic complications [40].
A local study conducted in an endocrine clinic in a
teaching hospital in Kuala Lumpur identified barriers to
optimal control of Malay type 2 diabetic patients by
interviewing 18 patients and health care providers. It
was not surprising to find that most of the patients had
a lack of understanding of the disease itself and of its
management, which would eventually contribute to non-
adherence [41]. This is particularly true for the elderly as
they tend to have decreased memory, health beliefs not
in line with drug therapy, and often neglect the import-
ance of adherence to medications and dietary control.
Hence, counseling may be important to increase the
awareness and knowledge of this patient population
since they frequently encounter these problems.
Causes of DRPs
The results from our study revealed that among all the
causes, “drug or dose selection” was the most frequently
identified cause for DRPs such as drug choice problems,
dosing problems or drug interactions. According to the
PCNE classification of DRPs, this domain of causes is
directly related to the drug or dosage selection while the
other domains are concerned with patient-related causes
[22].
On the other hand, patients usually had “drug use pro-
blems” caused by “drug use process, lack of information,
and physiological or patient factor”. Generally, the num-
ber of causes identified was lower than the causes identi-
fied in other studies such as Chan et al. (2011) [21].
This is because most of the problems identified were
matched with the one most relevant cause rather than
several causes, which might be seen in other studies.
Factors found to be associated with DRPs
Generally, this study did not identify any factors with a
statistically significant association with DRP. This was in
agreement with a study by Koh et al. (2005) [39] whichfound no statistical correlation between DRPs and age
or gender. Research by Samoy et al. (2006) [42] also
concluded that there were no risk factors for drug-
related hospitalization in a tertiary care hospital in
Canada. One of the possible explanations is the nature
of the PCNE classification system (6 problem domains
with 22 categories) which could possibly affect the
results. Also, it remains unclear whether the result was
affected by the sample size (Samoy et al., 2006) [42].
When examining each of the problem domains with
several possible factors, statistically significant associa-
tions were observed. These associations should receive
the attention of the health care providers in order to
minimize preventable DRPs.
Elderly
In our study, the non-elderly were found to be associated
with drug choice problems. From the literature reviewed,
the findings on the association between age and DRPs are
conflicting. In one study on the elderly in an ambulatory
setting, age of 80 and above was found to be an independ-
ent risk factor for adverse drug events [43]. While a study
by Chan et al. (2011) [21] on geriatrics also reported a sig-
nificant association between age and DRPs, a few studies
did not agree with this finding. A study on hospitalized
patients from several internal medicine departments
found that age was not a risk factor of DRPs [15]. Simi-
larly, Koh et al. (2005) [39] did not report any statistically
significant correlation between these two.
Polypharmacy
It is a well-known fact that polypharmacy is strongly
associated with DRPs and this has been shown by nu-
merous studies [12,14,15,43]. It has been reported that a
one unit increase in the number of drugs can lead to an
increase of 8.6% in the number of DRPs [43].
The results of our study revealed a significant statis-
tical association between polypharmacy and drug inter-
actions, which was consistent with the result from
Moura et al. (2009) [44], a retrospective study on drug
interactions in a public hospital in Brazil. The increasing
number of drugs used can lead to an increased risk of
potential drug interactions [23,45]. Since polypharmacy
is an inherent problem in T2DM patients with hyperten-
sion, the clinically important and significant drug inter-
actions should be routinely checked and monitored [9].
Renal impairment
Renal impairment was associated with both the drug choice
problem (p = 0.029) and the dosing problem (p = 0.027).
Drugs with doses that were higher than required were often
prescribed to T2DM patients with hypertension and renal
impairment in our study. Also, dosage adjustment was
commonly ignored by physicians, suggesting that the
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be underestimated [36,37]. DRPs were common among
patients with renal impairment due to co-existing medical
conditions, as most of them were receiving multiple medi-
cations which require dosage adjustment and routine mon-
itoring [36].
The study by Manley et al. (2003) [32] revealed that in
ambulatory hemodialysis patients, the presence of diabetes
mellitus is one of the factors associated with DRPs. In other
words, diabetes patients on hemodialysis were more likely
to experience DRPs. Similarly, Leendertse el al. (2008) [14]
also found that impaired renal function was a risk factor
for potentially preventable DRPs. Therefore, in patients
with renal impairment, dosage adjustment and close moni-
toring of renal function are fundamental in order to
minimize drug toxicity or subtherapeutic effect [46].
Cardiovascular events
Patients with cardiovascular events had more potential
drug interactions than patients without cardiovascular
disease in our study. This can be explained by the wide
use of cardiovascular drugs such as antihypertensive
drugs, antiplatelet drugs, anticoagulants, and lipid lower-
ing drugs in T2DM patients with hypertension. Many
studies concluded that the most common drug category
involved in DRPs was cardiovascular agents [12,47].
Also, cardiovascular events often add an additional bur-
den to patient conditions and complicate their therapies.
Duration of stay
Patients who stayed for not more than one week in the
hospital tended to experience the drug choice problem
as compared with those who stayed for more than one
week. This finding of our study was not in line with that
reported by Moura et al. (2009) [44], which revealed an
association between duration of hospital stay and poten-
tial drug interactions.
Another study on hospitalized cancer patients also
found a correlation between duration of hospital stay
(≥ 6 days) and potential interactions [48]. The relation-
ship between length of hospital stay and DRPs needs to
be investigated in future studies since there is a lack of
published literature investigating this association.
Study limitations
Because of the retrospective nature of our study, the identi-
fication and assessment of the DRPs were based on the data
available from the medical records with reference to estab-
lished literature and guidelines. The number of studied
patients was less than 50% of potentially eligible patients.
Conclusions
The most common drugs that were used in T2DM patients
with hypertension were amlodipine, insulin, aspirin andsimvastatin. Polypharmacy and multiple comorbidities
were common in this patient population.
The most common DRPs were “others” (i.e., insuffi-
cient awareness of health and diseases), drug choice pro-
blems, dosing problems, and drug interactions. The
most implicated drugs were aspirin, clopidogrel, simvas-
tatin, amlodipine and metformin.
Several factors were found to have statistically signifi-
cant associations with the six domains of DRPs, includ-
ing renal impairment, polypharmacy, cardiovascular
disease, elderly age, and duration of hospital stay.
Special attention should be given to T2DM patients
with hypertension and risk factors who are prescribed
commonly implicated drugs.
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